Jefferies upgrades Medifast [MED] to Buy rating with a $265 price target
Jefferies took its Medifast [MED] rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research note dated 2021-01-25. That figure represents around a 19.91% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with B. Riley FBR’s analysts assigning […]
